Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

PVL after TTVR linked to much lower survival rate, fewer clinical benefits
TTVR has made a major impact on heart patients all over the world. Just like aortic and mitral valve replacement, however, paravalvular leak is a serious complication that can lead to much worse outcomes.
SVS quality initiative gathers data to improve vascular care
More than 7,000 physicians from a wide variety of healthcare specialties are already participating in the project.
Post-TAVR bleeding in AFib patients much less common with apixaban than rivaroxaban
When it came to all-cause mortality and ischemic stroke, however, the two popular DOACs were associated with comparable outcomes.
Medline recalls millions of devices due to safety risk—FDA threatens ‘regulatory action’ in warning letter
Millions of angiographic syringes were recalled due to a risk of parts becoming loose or disconnected. The FDA, unhappy with Medline's response to this situation, sent the company a new warning letter.
FDA clears way for IDE pivotal trial of the Topaz tricuspid valve replacement system
The TRiCares Topaz uses a unique two-stent frame valve prosthesis for better sealing and flexibility.

Edwards Evoque transcatheter tricuspid valve replacement TTVR

American College of Cardiology shares new expert recommendations on treating tricuspid regurgitation

There have been so many developments in the treatment of TR that it can be challenging to keep up. The ACC crafted this new document to help ensure cardiologists, cardiac imagers and other clinicians have access to the most recent clinical data and policy decisions.

warning safety alert recall healthcare issue

FDA investigating Johnson & Johnson medical devices again after 5 injuries

To address this latest safety concern, the third in three months, the company is updating each device and then returning it to the customer.

Safety concern with Johnson & Johnson heart pump controllers leads to Class I recall

Some controllers were assembled with an incorrect part, potentially impacting device performance. The FDA shared an early alert about this issue in August. It has been linked to one patient's death.

SCAI takes on shock-related mortality with door-to-lactate clearance initiative

The new initiative aims to provide shock teams with objective data that can guide early management decisions and reduce mortality rates.

Stroke risk much higher for TAVR patients with carotid artery stenosis

Screening TAVR patients for CAS may provide significant value, according to a new meta-analysis of 15 different studies.

artificial intelligence AI predictive analytics

Top US heart hospital launches new AI research lab

Mount Sinai Fuster Heart Hospital aims to take its use of AI during interventional procedures to the next level and find new ways to transform patient care.

Kimberly Campbell, RN, ANP-BC, nurse practitioner, Saint Luke's Cardiovascular Consultants, explains how her health system took a heart team approach in its wound care transition program for peripheral artery disease (PAD) and critical limb ischemia (CLI) patients that lowered their amputation rate my more than 50%.

St. Luke’s cuts PAD amputation rate in half with heart team-led wound transition program

Kimberly Campbell, RN, nurse practitioner, Saint Luke's Cardiovascular Consultants, explains how her health system took a heart team approach toward peripheral artery disease.

World’s most populous country gains access to Medtronic’s newest TAVR valve

Medtronic developed the self-expanding Evolut FX+ TAVR system with improved coronary access in mind. The FDA-approved device has now officially launched in India.

Interventional Cardiology

PVL after TTVR linked to much lower survival rate, fewer clinical benefits

SVS quality initiative gathers data to improve vascular care

Post-TAVR bleeding in AFib patients much less common with apixaban than rivaroxaban

Medline recalls millions of devices due to safety risk—FDA threatens ‘regulatory action’ in warning letter

FDA clears way for IDE pivotal trial of the Topaz tricuspid valve replacement system